Alyssa Starek
Neurology · Stuart, FLNPI 1346749447
Payments from drug & device makers
Across 523 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biogen$757
- Novartis$624
- UCB, Inc.$527
- Pfizer$498
- Acadia Pharmaceuticals Inc$454
- plus $5K from 47 others
What the payments were for
- Food & beverage$9,362100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADUHELM$109
How this compares
$9,377 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 25 | $246,603 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $129,648 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $92,175 |
| IngrezzaValbenazine Tosylate | 11 | $91,830 |
| QuliptaAtogepant | 28 | $53,742 |
| AptiomEslicarbazepine Acetate | 24 | $46,466 |
| Nurtec OdtRimegepant Sulfate | 12 | $30,183 |
| UbrelvyUbrogepant | 17 | $25,052 |
| Emgality PenGalcanezumab-Gnlm | 26 | $17,809 |
| RytaryCarbidopa/Levodopa | 21 | $13,452 |
| Gabapentin | 216 | $3,783 |
| Donepezil Hcl | 158 | $2,936 |
| AmantadineAmantadine Hcl | 18 | $2,667 |
| Memantine Hcl | 102 | $2,025 |
| Primidone | 58 | $1,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $171 | $129,64816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $59 | $92,17518 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $69 | $91,83011 claims |
| AbbVieQulipta, Ubrelvy | $1,796 | $78,79345 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $155 | $46,46624 claims |
| PfizerNurtec Odt | $498 | $30,18312 claims |
| Amneal Pharmaceuticals LLCRytary | $107 | $13,45221 claims |
| Upsher-smith Laboratories LLCTopiramate | $63 | $76662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.
Other neurology in Stuart
- Adam FalchookStuart$7.3M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.